27
total announcements
ONESOURCE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹15,671 Cr
P/E (Forward)
18.1
EPS (TTM)
₹-4.25
52W Low
₹1,057.00
52W High
₹1,925.00
Dividend Yield
0.00%
Price / Book
2.7
Debt / Equity
25.8
Revenue (TTM)
₹1,543 Cr
Gross Margin
67.99%
Operating Margin
11.49%
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the auditor's review report stating that nothing has come to their attention that causes them to believe the financial statements contain any material misstatement.
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited announced an earnings call scheduled for July 25, 2026 at 10:00 IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The call will be led by CEO & MD Neeraj Sharma and CFO Anurag Bhagania. Dial-in numbers and a DiamondPass link for early registration were provided in the announcement. This is a routine procedural update with no new financial information disclosed.
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited has entered into a strategic manufacturing partnership with Formycon AG for biosimilars. The partnership will enable OneSource to provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities to Formycon. The collaboration aims to expand access to high-quality, affordable biologics for patients worldwide.
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited has clarified that the delay in commercial supplies of Semaglutide by Dr. Reddy's Laboratories (DRL) will not have a material impact on their operations, citing sufficient demand from other customers and upcoming capacity additions.
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has informed the Exchange about the allotment of 24,190 equity shares under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 to eligible employees upon exercise of vested options, increasing the paid-up share capital from INR. 11,46,45,801 to INR. 11,46,69,991.
Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited has informed the Exchange regarding the completion of a US-FDA inspection at its Sterile Product Division facility in Bengaluru, with one observation noted and a comprehensive response to be submitted within the stipulated time frame.
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.